# Allostatic Load, Single, and Dual Chronic Conditions: Evidence from the National Health and Nutrition Examination Survey 

Peter Memiah, DrPH, MSc, ${ }^{1}$ Sibhatu Biadgilign, PhD, ${ }^{2}$ Jamie Kuhlman, BSc, ${ }^{3}$ Courtney Cook, BSc, ${ }^{4}$ Piera Mburia, PhD, ${ }^{5}$ Carol Kingori, PhD, ${ }^{3}$ Daniel Sarpong, PhD, ${ }^{6}$ Gabriel Buluku, MD, ${ }^{7}$ and Marquis Hawkins, $\mathrm{PhD}^{8}$


#### Abstract

Background: Allostatic load (AL) is defined as a cumulative burden of chronic stress and life events, which involves the interaction of different physiological systems at varying degrees of activity. AL is suspected of contributing to health disparities among different populations. Suppressed or overactive physiological systems can interrupt AL affecting proper tissue and organ function leading to disease. The objective of our study was to determine the association of AL with dual chronic conditions. Methods: We used data from the National Health and Nutrition Examination Survey (NHANES). For the current analysis, we used the data cycles of 2007-2010, which is the most recent data that collected comprehensive measures of the composite AL outcome variable. Descriptive, bivariate, and multivariable logistic regression, with stepwise forward variable selection method ( $P<0.05$ ), were conducted using STATA/IC 15.0. Results: AL levels were high among $20 \%$ of the respondents ( $n=2179$ ). Having a lower income to poverty ratio, being married, physical inactivity, experiencing sleep problems, and a history of smoking were significantly associated with high AL ( $P<0.05$ ). Non-Hispanic blacks [odds ratio (OR): $1.8 ; 95 \%$ confidence interval (CI): 1.6-2.4] and Mexicans and other Hispanics (OR: 1.4; 95\% CI: 1.1-1.7) had higher AL compared to Caucasians. Having cardiovascular disease (CVD) (OR: 1.7; 95\% CI: 1.4-2.2) and diabetes (OR: 4.7; 95\% CI: 3.8-5.7) independently, as well as both CVD and diabetes (OR: 3.1; 95\% CI 2.7-3.6), were associated with higher odds of AL. We conducted an age-adjusted regression model that indicated higher odds of elevated AL among females with diabetes independently (OR: 1.4;95\% CI: 1.2-1.9) and with both CVD and diabetes (OR: $1.6 ; 95 \%$ CI: 1.2-2.1) compared to men. Conclusions: Despite the significant impact and association of AL with overall health, there is minimal evidence of its risk factors and linkage to disease burden. Modifiable lifestyle factors were associated with a higher AL. There is a critical need to support ethnic and gender contextual interventions to reduce the burden of AL on chronic conditions.


[^0]Keywords: allostatic load, diabetes, cardiovascular disease, NHANES, race

## Introduction

ALlostatic load (AL) Refers to the cumulative burden of chronic stress and life events. It involves the interaction of different physiological systems at varying degrees of activity. When environmental challenges exceed the individual ability to cope, then allostatic overload ensues. The health disparities with risk factors lead to allostatic dysregulation with maladaptive physiological (including hypothalamo-pituitary-adrenal axis, sympathetic nervous system, and the immune system) and behavioral responses culminating in allostatic loading and, ultimately, to diseased states such as with cardiovascular disease (CVD). ${ }^{1} \mathrm{AL}$ is identified by the use of biomarkers and clinical criteria.

Chronic disease leads to poor overall health, disability, and death, accounting for most health care expenditures in the United States. ${ }^{2,3}$ Approximately half (50.9\%) of adults have at least one chronic condition, with $26 \%$ having two or more chronic conditions. ${ }^{4}$ Cross sectional evidence shows that high AL is associated with CVD, ${ }^{5,6}$ periodontal disease, ${ }^{6}$ chronic fatigue syndrome, and diabetes. ${ }^{7}$ In longitudinal studies, high AL is predictive of all-cause mortality ${ }^{8}$ and lower cognitive and physical functioning. ${ }^{9}$ With limited evidence on whether AL is higher among those with multiple chronic diseases or not, this study aims to examine the association of AL with CVD or diabetes or both conditions using the National Health and Nutrition Examination Survey (NHANES) study. We further assess race/ethnic comparisons while adjusting for potential confounders.

## Methods

## Study design and population

NHANES is a cross sectional, observational study of noninstitutionalized U.S. residents conducted by the $\mathrm{Na}-$ tional Center for Health Statistics of the Centers for Disease Control and Prevention (CDC). NHANES uses a stratified, multistage probability design to obtain a nationally representative sample of the U.S. population. Non-Hispanic black and Hispanic individuals, persons 60 years of age and older, and individuals of low-income are oversampled to produce those nationally representative estimates. ${ }^{7}$ We used the most recent NHANES data cycles of 2007-2010, with complete measures of AL, described in detail below. We restricted our sample to participants with data on the primary outcome variables (i.e., diabetes and CVD). The National Center for Health Statistics Institutional Review Board approved this protocol. All participants provided written informed consent at the time of the household interview.

## Allostatic load

All measures for AL were collected using a mobile examination center by a trained technician using standardized procedures. AL was calculated as the sum of 11 indicators of biological functioning across a range of regulatory systems, including systolic blood pressure (SBP) $(\geq 140 \mathrm{mmHg})$ and diastolic blood pressure ( $>90 \mathrm{mmHg}$ ) (cardiovascular system); plasma high-density lipoprotein cholesterol (HDLC) $(<30 \mathrm{mg} / \mathrm{dL})$, triglycerides $(\geq 150 \mathrm{mg} / \mathrm{dL})$, total cholesterol
(TC) $(\geq 250 \mathrm{mg} / \mathrm{dL})$, serum albumin $(\leq 3.9 \mathrm{mg} / \mathrm{dL})$, c-reactive protein ( $\geq 0.33 \mathrm{mg} / \mathrm{dL}$ ), fibrinogen ( $>336 \mathrm{mg} / \mathrm{dL}$ ), creatinine clearance ( $\leq 16.49 \mathrm{mg} / \mathrm{dL}$ ), and glycohemoglobin ( $>5.6 \%$ ) (lipid metabolism and long-term atherosclerotic risk); and body mass index (BMI) ( $\geq 30 \mathrm{~kg} / \mathrm{m}^{2}$ ) (adipose tissue deposition). ${ }^{10}$ High AL was defined as having three or more of these indicators.

## Diabetes

Diabetes was defined as self-reported physician-diagnosed diabetes. Participants were asked to report the age they were diagnosed. Duration of diabetes was categorized as 5 or younger, 5 to 9 , and 10 or more years.

## Cardiovascular disease

CVD was defined as a self-reported history of congestive heart failure, coronary heart disease, angina, myocardial infarction, or stroke.

## Covariates

Demographic characteristics were collected through self-report during the household examination and included age ( $20-29,30-49,50-64,65-74, \geq 75$ years), race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic (i.e., Mexican American and other Hispanic), and other - including biracial), marital status (married/living with partner, single), and income to poverty ratio ( $<1.3,1.3-3.5,>3.5$ ). The income to poverty ratio was created using the Department of Health and Human Services poverty guidelines. ${ }^{11}$ The participants' family monthly income was divided by the poverty guidelines, which takes into account family size.

Behavioral characteristics included physical activity (PA) (inactive, insufficiently active, meeting PA (active and highly active) guidelines), ${ }^{12}$ self-reported trouble sleeping, current smoking status (nonsmoker, former smoker, never smoker), and alcohol intake (nondrinker, moderate drinker, excessive drinker). PA was assessed using a modified Global Physical Activity Questionnaire. ${ }^{8}$ Participants were asked to report the frequency and duration of engaging in any vigorous-intensity sports, fitness, or recreational activities that cause large increases in breathing or heart rate like running or basketball for at least 10 min continuously in a typical week. We defined participants as inactive if they reported no PA, insufficiently active if they reported $>0$ to $<150 \mathrm{~min} /$ week of PA, and meeting guidelines for PA if they reported $\geq 150 \mathrm{~min} /$ week of PA. ${ }^{12}$

Alcohol intake was assessed as the average number of alcohol drinks/day in the past 12 months. We defined participants as nondrinkers, if they reported not drinking in the past 12 months or in their lives, and moderate drinkers, if they reported drinking less than 4 or 5 drinks/day in men and women. Participants were defined as excessive drinkers if they drank more than 4 or 5 drinks/day in men and in women. ${ }^{13}$

Other health conditions included self-reported doctordiagnosed liver disease, cancer, weak/failing kidneys, and general health status. General health condition was defined as self-reported excellent/very good, good/fair, or poor
health. Participants also reported the number of days they did not have good physical or mental health in the past month.

## Statistical analysis

We used descriptive statistics to compare characteristics of the population by diabetes and by CVD status. Chi-square was used for categorical variables and Student's $t$-test for continuous variables. For the main analysis, multivariable logistic regression, with stepwise forward variable selection method ( $P<0.05$ ) was used to compare the odds of high AL by race and age stratified by gender. We repeated these analyses with diabetes and CVD status as the independent variables, adjusting for age. To test for effect modification, we stratified the analyses by gender and race/ethnicity. The complex survey design used for NHANES data collection was incorporated into all data analysis using STATA/IC 15.0 (StataCorp LP: College Station, TX). All analyses were conducted in 2018 and considered statistically significant at an alpha of 0.05 .

## Results

Table 1 describes the demographic characteristics of the population by chronic disease status. Age, ethnicity/race, and income to poverty ratio were significantly $(P<0.001)$ associated with having CVD, diabetes, and both chronic conditions (CVD and diabetes). Specifically, a significantly ( $P<0.001$ ) higher proportion of respondents $50-64$ years old had CVD, diabetes, and both chronic conditions ( $30.5 \%$, $37 \%$, and $34 \%$, respectively) versus those $20-29$ years old ( $1.7 \%, 2.6 \%$ and $2.5 \%$, respectively). There were significant ( $P<0.001$ ) gender differences in respondents who reported having CVD with $56.2 \%$ being men and $43.9 \%$ women, but no significant gender differences were observed in respondents who had CVD, diabetes, and both chronic conditions (Table 1).

## Association of CVD, diabetes, and both chronic conditions across behavioral characteristics

Table 2 describes the behavioral characteristics of the population by chronic disease status. Participants who met guidelines for PA had significantly $(P<0.001)$ lower prevalence of CVD ( $7 \%$ ), diabetes ( $6.3 \%$ ), and both chronic conditions ( $7.2 \%$ ) than physically inactive participants ( $63.2 \%, 66.1 \%$, and $63 \%$, respectively). Among the respondents who reported sleep problems, a significantly ( $P<0.001$ ) higher proportion had CVD, diabetes, and both chronic conditions (41.5\%, 34.8\%, and $36.6 \%$, respectively) compared to those who did not ( $58.5 \%, 65.2 \%$, and $63.4 \%$, respectively) (Table 2).

## Association of CVD, diabetes, and both chronic conditions across health-related conditions and biomarkers

Table 3 indicates that respondents who reported having liver disease, cancer, and weak or failing kidneys had a significant association with CVD, diabetes, and both CVD and diabetes $(P<0.001)$. Other factors that were significantly associated with the three (CVD, diabetes, and both chronic diseases) included respondent perception of physical health and general health; obesity as measured by

BMI; low-density lipoprotein (LDL) cholesterol; HDL-C; triglycerides; SBP; hypertension; albumin; CRP; and AL ( $P<0.001$ ).

## Correlates of CVD, diabetes, or both chronic diseases

As shown in Table 4, non-Hispanic blacks were almost two times more likely to have a higher AL compared to the non-Hispanic white population (adjusted odds ratio [aOR] = 1.99 , $95 \%$ confidence interval [CI]: 1.64-2.41), while Mexicans and other Hispanics were 1.42 times more likely to have both a higher AL compared to the non-Hispanic white population $(\mathrm{aOR}=1.42,95 \% \mathrm{CI}: 1.13-1.77)$. Having an income to poverty ratio of $<1.3$ was ( $24 \%$ ) less likely associated with high $\mathrm{AL}(\mathrm{aOR}=0.76,95 \% \mathrm{CI}: 0.65-0.89)$ compared to having an income to poverty ratio of greater than 3.5. With regard to marital status, the odds of having a lower AL were significantly ( $18 \%$ ) lower among respondents whose marital status was single ( $\mathrm{aOR}=0.82,95 \% \mathrm{CI}$ : $0.75-0.91$ ) compared to those who were married (Table 4).
Respondents who reported being physically inactive were more likely to have higher $\mathrm{AL}(\mathrm{aOR}=1.54,95 \% \mathrm{CI}$ : $1.49-$ 1.60) compared to those who reported meeting the physical exercise guidelines. Respondents who reported experiencing sleep problems were significantly $(\mathrm{aOR}=1.39,95 \% \mathrm{CI}$ : 1.21-1.59) more likely to have a higher AL compared to those who reported having no sleep problems. Respondents who reported being past smokers were significantly more likely $(\mathrm{aOR}=1.40,95 \% \mathrm{CI}: 1.21-1.62)$ to have a higher AL compared to the nonsmokers. Nondrinkers were less likely $(\mathrm{aOR}=0.54,95 \% \mathrm{CI}: 0.46-0.62)$ to have a higher AL compared to excessive drinkers. Respondents with no weak/ failing kidneys were ( $53 \%$ ) less likely ( $\mathrm{aOR}=0.47,95 \% \mathrm{CI}$ : $0.37-0.42$ ) to have a higher AL compared to those with weak/failing kidneys.

Those who reported not having good mental health and physical health in the past 2 weeks were more likely to have a higher $\mathrm{AL}(\mathrm{aOR}=1.67,95 \% \mathrm{CI}: 1.38-1.89$ and $\mathrm{aOR}=$ 1.37, $95 \%$ CI: 1.17-1.60, respectively). Low HDL-C was associated with higher $\mathrm{AL}(\mathrm{aOR}=1.40,95 \% \mathrm{CI}: 1.18-1.66)$. Those who had CVD were more likely to have a higher AL ( $\mathrm{aOR}=1.74,95 \% \mathrm{CI}: 1.39-2.18$ ); furthermore, respondents who had diabetes were more likely to have a higher AL ( $\mathrm{aOR}=4.67,95 \% \mathrm{CI}: 3.79-5.74$ ).
Finally, those with both conditions (CVD and diabetes) were more likely to have a higher AL compared to those who had neither $(\mathrm{aOR}=3.13,95 \% \mathrm{CI}: 2.71-3.62)$ (Table 4). We further conducted an age-adjusted analysis model whereby there were higher odds of elevated AL among females with diabetes independently (OR: 1.4; $95 \%$ CI: 1.21.9 ) and women with both CVD and diabetes (OR: 1.6; 95\% CI: 1.2-2.1) compared to men.

## Discussion

The findings revealed that there is a significant association of AL with diabetes, CVD, and having both conditions. The association between high AL and CVD in our study is also evident in other similar settings that show increased AL (excluding respective definitive parameters) being significantly associated with higher odds of hypertension, diabetes, and self-reported CVD. ${ }^{5}$ The presence of AL mainly manifests a greater array of varied health outcomes such as CVD and mortality. ${ }^{14}$
Table 1. Association of Cardiovascular Disease, Diabetes, and Both Chronic Conditions Across Demographic Characteristics

| Variable | $C V D$ |  |  | Diabetes |  |  | CVD/diabetes |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | No n (\%) | Yes n (\%) | (P-value) | No n (\%) | Yes n (\%) | (P-value) | No n (\%) | Yes n (\%) | (P-value) |
| Age, years |  |  |  |  |  |  |  |  |  |
| 20-29 | 1652 (20.4) | 15 (1.7) | (<0.001**) | 1650 (20.4) | 17 (2.6) | (<0.001**) | 1635 (21.6) | 32 (2.5) | 2590.38 (<0.001**) |
| 30-49 | 3422 (40.8) | 113 (13.3) |  | 3351 (40.2) | 184 (20.4) |  | 3262 (41.9) | 273 (18.1) |  |
| 50-64 | 2346 (25.6) | 306 (30.5) |  | 2198 (25) | 454 (37.3) |  | 2002 (24.6) | 650 (34.6) |  |
| 65-74 | 1069 (8.3) | 313 (26) |  | 1036 (8.4) | 346 (25) |  | 837 (73.4) | 545 (24.4) |  |
| >75 | 701 (4.9) | 357 (28.5) |  | 851 (6.1) | 207 (14.8) |  | 595 (4.6) | 463 (20.4) |  |
| Gender |  |  |  |  |  |  |  |  |  |
| Male | 4431 (47.7) | 666 (56.2) | (<0.001**) | 4483 (48.3) | 614 (49.7) | (0.542) | 4011 (47.7) | 1086 (52.9) | 27.540 (0.008) |
| Female | 4842 (52.3) | 472 (43.9) |  | 4699 (51.7) | 615 (50.3) |  | 4388 (52.3) | 926 (47.1) |  |
| Race |  |  |  |  |  |  |  |  |  |
| Non-Hispanic white | 4379 (69.3) | 693 (77.2) | (<0.001**) | 4585 (70.5) | 487 (63.1) | (<0.001**) | 4072 (70) | 1000 (70) | 43.560 (0.011**) |
| Non-Hispanic black | 1641 (10.3) | 204 (10.8) |  | 1545 (9.8) | 300 (15.7) |  | 1423 (9.8) | 422 (13) |  |
| Mexican and Other Hispanic | 2808 (14.1) | 201 (7.3) |  | 2622 (13.5) | 387 (14) |  | 2501 (14) | 508 (11) |  |
| Other | 445 (6.4) | 40 (4.8) |  | 430 (6.2) | 55 (7.2) |  | 403 (6.2) | 82 (6) |  |
| Income to poverty ratio |  |  |  |  |  |  |  |  |  |
| $<1.3$ | 2633 (20.1) | 370 (26.1) | (<0.001**) | 2618 (20.3) | 385 (24.1) | (<0.001**) | 2376 (20) | 627 (24.4) | 115.525 (<0.001**) |
| 1.3-3.5 | 3202 (35.4) | 433 (41.5) |  | 3170 (35.3) | 465 (42.6) |  | 2870 (35) | 765 (41.5) |  |
| >3.5 | 2620 (44.5) | 233 (32.4) |  | 2600 (44.4) | 253 (33.3) |  | 2426 (45) | 427 (34.1) |  |
| Marital status |  |  |  |  |  |  |  |  |  |
| Single | 3613 (35.3) | 490 (38.5) | (0.084) | 3592 (35.3) | 511 (37.7) | (0.196) | 3270 (35.3) | 833 (36.9) | 2.799 (0.276) |
| Married/living with partner | 5655 (64.7) | 648 (61.4) |  | 5587 (64.7) | 716 (62.3) |  | 5126 (64.7) | 1177 (63.1) |  |

[^1]Table 2. Association of Cardiovascular Disease, Diabetes, and Both Chronic Conditions Across Behavioral Characteristics

| Variable | $C V D$ |  |  | Diabetes |  |  | CVD/diabetes |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | No n (\%) | Yes n (\%) | (P-value) | No n (\%) | Yes n (\%) | Test statistic (P-value) | No n (\%) | Yes n (\%) | Test statistic (P-value) |
| PA |  |  |  |  |  |  |  |  |  |
| Inactive | 4958 (46.1) | 779 (63.2) | (<0.001**) | 4858 (45.8) | 879 (66.1) | (<0.001**) | 4357 (45) | 1380 (63) | (<0.001**) |
| Insufficiently active | 3016 (37.3) | 299 (29.8) |  | 3017 (37.5) | 298 (27.6) |  | 2788 (37.8) | 527 (29.8) |  |
| Meeting guidelines | 1288 (16.6) | 59 (7) |  | 1295 (16.7) | 52 (6.3) |  | 1243 (17.2) | 104 (7.2) |  |
| Sleep problems |  |  |  |  |  |  |  |  |  |
| No | 7207 (76.2) | 671 (58.5) | $\left(<0.001^{* *}\right)$ | 7067 (75.7) | 811 (65.2) | (<0.001**) | 6585 (76.7) | 1293 (63.4) | (<0.001**) |
| Yes | 2062 (23.8) | 466 (41.5) |  | 2110 (24.4) | 418 (34.8) |  | 1810 (23.3) | 718 (36.6) |  |
| Smoking |  |  |  |  |  |  |  |  |  |
| Nonsmoker | 5082 (55.2) | 435 (39.5) | $\left(<0.001^{* *}\right)$ | 4906 (54.4) | 611 (48.7) | (<0.001**) | 4610 (55.4) | 907 (44.7) | (<0.001**) |
| Past | 2143 (23.3) | 463 (40.4) |  | 2185 (23.8) | 421 (34.7) |  | 1874 (22.7) | 732 (37.1) |  |
| Current | 2043 (21.5) | 240 (20.2) |  | 2087 (21.8) | 196 (16.6) |  | 1911 (21.9) | 372 (18.2) |  |
| Alcohol |  |  |  |  |  |  |  |  |  |
| Nondrinker | 2700 (25.7) | 522 (45) | 308.635 (<0.001**) | 2585 (25.2) | 637 (50.6) | (<0.001**) | 2260 (24) | 962 (46) | (<0.001) |
| Moderate drinking | 4711 (60.1) | 466 (48.8) |  | 4738 (60.6) | 439 (42.9) |  | 4389 (61) | 788 (47) |  |
| Excessive drinking | 1280 (14.2) | 73 (6.2) |  | 1269 (14.2) | 84 (6.5) |  | 1212 (15) | 141 (7) |  |

The study findings indicate that being a past smoker and having excessive drinking habits increase the chance of having high AL. Recent literature associates frequent alcohol use with components of AL. ${ }^{15}$ Reciprocally, the higher level of AL compromises positive health behaviors through stress experiences and through damaging behaviors such as tobacco and alcohol abuse that frequently accompany chronic stress states. ${ }^{16}$ Similarly, there is a link between physiological indicators of stress to future morbidity and mortality from cardiometabolic disorders such as diabetes. ${ }^{17}$ Redundant exposure to stress demonstrates excess secretion of glucocorticoids and catecholamines and increases the risk for diabetes and CVD. ${ }^{18}$ This reflects on AL score with a direct measure of stress-induced cardiovascular, metabolic, and immune biomarkers resulting in greater physiological dysfunction. ${ }^{18,19}$

In our study, lower income or poverty level was associated with high AL. Other findings have documented that higher socioeconomic status promotes some healthy behaviors and is associated with lower AL. ${ }^{20}$ This finding is also supported by other research findings, in which households with incomes below the poverty line are positively associated with higher AL; this, therefore, presents long-term health implications of living in neighborhoods with high concentrations of poverty apart from the household income level. ${ }^{21,22}$ However, the relationship between poverty and AL may also be mediated through stressors associated with neighborhood conditions but not merely on the psychological stress manifestation. ${ }^{23}$

In this study, those who are physically inactive or do not meet the physical exercise guidelines were reported to have a high AL. It has been documented that individual lifestyle habits such as diet, exercise, substance abuse, and developmental experiences set life-long behavior patterns and physiological reactivity 24 associated with AL. Having low levels of PA and stressful events of daily life elevates and sustains activities of physiological systems that can cause sleep deprivation, overeating, and other health-damaging behaviors, producing the feeling of being "stressed out." 25 This finding is also reinforced through current literature indicating that highly active participants had lower AL and inflammatory risk than sedentary participants with meeting versus not meeting physical exercise guidelines. ${ }^{26}$

Our findings indicate that sleep deprivation/having sleeping problems is associated with higher levels of AL. Sleep deprivation and circadian disruption can be stressors, enhancers of other stressors that have consequences for the brain and many body systems, contributing to the cumulative wear and tear on body systems caused by too much stress. ${ }^{27}$ Evidence from the 2005 to 2008 NHANES revealed that after adjustment for sociodemographic and lifestyle factors and depression status, high AL was significantly associated with sleep apnea, snoring, snorting/stopping breathing, prolonged sleep latency, short sleep duration ( $<6 \mathrm{hr}$ ), and diagnosed sleep disorder. ${ }^{28}$

Other findings have demonstrated that inadequate or problematic sleep can be taken as a neurobiological and physiologic stressor. ${ }^{29}$ Others argue that sleep by itself is considered a component to construct $\mathrm{AL} .{ }^{30}$ The literature review suggests that in any case, there might be a bidirectional association between AL and sleep disturbances in that sleep deprivation and poor sleep quality associated with stresses may contribute to AL. High AL might also contribute to sleep disturbances. ${ }^{9}$
Table 3. Association of Cardiovascular Disease, Diabetes, and Both Chronic Conditions Across Health-Related Conditions and Biomarkers

| Variable | CVD |  |  | Diabetes |  |  | CVD/diabetes |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | No n (\%) | Yes n (\%) | (P-value) | No n (\%) | Yes n (\%) | (P-value) | No n (\%) | Yes n (\%) | (P-value) |
| Liver diseases |  |  |  |  |  |  |  |  |  |
| No | 8984 (97.5) | 1058 (93.5) | 87.014 (<0.001**) | 8881 (97.3) | 1161 (95.2) | 25.067 (0.012**) | 8150 (97.6) | 1892 (94.4) | 88.683 (<0.001**) |
| Yes | 277 (2.6) | 75 (6.5) |  | 290 (2.7) | 62 (4.8) |  | 240 (2.4) | 112 (5.6) |  |
| Cancer |  |  |  |  |  |  |  |  |  |
| No | 8513 (91.9) | 878 (76.9) | 409.999 (<0.001**) | 8349 (91.3) | 1042 (83.8) | 102.112 (<0.001**) | 7743 (92.2) | 1648 (81.2) | 359.228 (<0.001**) |
| Yes | 751 (8.1) | 258 (23.1) |  | 825 (8.7) | 184 (16.2) |  | 650 (7.8) | 359 (18.8) |  |
| Weak/failing kidneys |  |  |  |  |  |  |  |  |  |
| No | 9095 (98.7) | 1035 (91.9) | 406.109 (<0.001**) | 9001 (98.6) | 1129 (93.6) | 214.022 (<0.001**) | 8269 (98.9) | 1861 (93.8) | 361.916 (<0.001**) |
| Yes | 163 (1.3) | 101 (8.1) |  | 171 (1.4) | 93 (6.4) |  | 120 (1.1) | 144 (6.2) |  |
| Physical health not good (past month), days |  |  |  |  |  |  |  |  |  |
| $<15$ | 7809 (85.8) | 820 (74.1) | 165.177 (<0.001**) | 7692 (85.6) | 937 (76.9) | 90.926 (<0.001**) | 7108 (86.1) | 1521 (77.2) | 154.782 (<0.001**) |
| 15-30 | 1464 (14.2) | 318 (25.9) |  | 1490 (14.4) | 292 (23.1) |  | 1291 (13.9) | 491 (22.8) |  |
| Mental health not good (past month), days |  |  |  |  |  |  |  |  |  |
| $<15$ | 7724 (83.9) | 901 (79.3) | 24.315 (0.006) | 7631 (83.8) | 994 (81.1) | 8.229 (0.056) | 7005 (84.1) | 1620 (80.5) | 22.869 (0.003**) |
| 15-30 | 1549 (16.1) | 237 (20.7) |  | 1551 (16.2) | 235 (18.9) |  | 1394 (15.9) | 392 (19.5) |  |
| General health condition |  |  |  |  |  |  |  |  |  |
| Excellent, very good | 3338 (46.9) | 190 (20.2) | 748.295 (<0.001**) | 3360 (47.2) | 168 (17.1) | 863.912 (<0.001**) | 3199 (48.8) | 329 (20.2) | 1219.544 (<0.001**) |
| Good/fair | 5112 (50.9) | 745 (68.7) |  | 4995 (50.7) | 862 (71.8) |  | 4495 (49.5) | 1362 (69.9) |  |
| Poor | 261 (2.2) | 136 (11.1) |  | 261 (2.1) | 136 (11.1) |  | 184 (1.7) | 213 (9.9) |  |
| Duration of diabetes, years |  |  |  |  |  |  |  |  |  |
| <5 | 8688 (95.9) | 877 (80.3) | 748.997 (<0.001**) | 9182 (100) | 383 (34.9) | 1300.4 (<0.001**) | 8399 (100) | 1166 (62.1) | 7120.757 (<0.001**) |
| 5 to 9 | 201 (1.4) | 83 (6.1) |  | 0 (0) | 284 (21.4) |  | 0 (0) | 284 (12.5) |  |
| $\geq 10$ | 384 (2.7) | 178 (13.6) |  | 0 (0) | 562 (43.7) |  | 0 (0) | 562 (25.5) |  |
| Obesity |  |  |  |  |  |  |  |  |  |
| No, BMI $<30 \mathrm{~kg} / \mathrm{m}^{2}$ | 5914 (66.3) | 618 (54.7) | 92.404 (<0.001**) | 6038 (67.9) | 494 (36.8) | 672.445 (<0.001**) | 5556 (68.3) | 976 (47.6) | 477.117 (<0.001**) |
| Yes, BMI $\geq 30 \mathrm{~kg} / \mathrm{m}^{2}$ | 3359 (33.7) | 520 (45.3) |  | 3144 (32.1) | 735 (63.2) |  | 2843 (31.7) | 1036 (52.4) |  |
| Waist to height ratio |  |  |  |  |  |  |  |  |  |
| 03 to $<0.5$ | 1610 (21.2) | 67 (6.7) | 347.237 (<0.001**) | 1649 (21.5) | 28 (3.8) | 837.738 (<0.001**) | 1587 (22.3) | 90 (5.8) | 867.949 (<0.001**) |
| 0.5 to $<0.7$ | 6374 (68.7) | 772 (71.3) |  | 6348 (69.2) | 798 (6.6) |  | 5794 (68.8) | 1352 (69.6) |  |
| $\geq 0.7$ | 1099 (10.1) | 238 (22) |  | 991 (9.4) | 346 (30.4) |  | 859 (8.9) | 478 (24.6) |  |
| HbA1C (\%) |  |  |  |  |  |  |  |  |  |
| <6.5 | 8428 (93.8) | 838 (76.9) | 649.435 (<0.001**) | 8830 (97.5) | 436 (37.1) | 8413.413 (<0.001**) | 8110 (97.8) | 1156 (60.3) | 5127.414 (<0.001**) |
| 6.5 to $<7.5$ | 453 (3.5) | 177 (14.1) |  | 248 (1.9) | 382 (31.6) |  | 200 (1.6) | 430 (20.7) |  |
| 7.5 to 8.9 | 206 (1.6) | 81 (5.8) |  | 52 (0.4) | 235 (18.9) |  | 42 (0.3) | 245 (11.5) |  |
| $\geq 9$ | 186 (1.1) | 42 (3.2) |  | 52 (0.3) | 176 (12.4) |  | 47 (0.3) | 181 (7.5) |  |
| Total cholesterol ( $\mathrm{mg} / \mathrm{dL}$ ) |  |  |  |  |  |  |  |  |  |
| Normal, <200 | 7932 (85.7) | 1003 (88.4) | 9.693 (0.075) | 7835 (85.6) | 1100 (89.8) | 23.000 (0.005) | 7155 (85.4) | 1780 (88.7) | 22.949 (0.018**) |
| High, $\geq 200$ | 1341 (14.3) | 135 (11.6) |  | 1347 (14.5) | 129 (10.2) |  | 1244 (14.6) | 232 (11.3) |  |

Table 3. (Continued)

| Variable | $C V D$ |  |  | Diabetes |  |  | CVD/diabetes |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | No n (\%) | Yes n (\%) | (P-value) | No n (\%) | Yes n (\%) | (P-value) | No n (\%) | Yes n (\%) | (P-value) |
| LDL cholesterol (mg/dL) |  |  |  |  |  |  |  |  |  |
| Normal, <100 | 7120 (76.7) | 785 (68.9) | 51.949 (<0.001**) | 7052 (76.8) | 853 (67.7) | 69.907 (<0.001**) | 6493 (77.2) | 1412 (69.3) | 84.858 (<0.001**) |
| High, $\geq 100$ | 2153 (23.3) | 353 (31.1) |  | 2130 (23.2) | 376 (32.2) |  | 1906 (22.8) | 600 (30.7) |  |
| HDL-C (mg/dL) |  |  |  |  |  |  |  |  |  |
| Low, <40 | 1412 (31.9) | 307 (55.7) | 297.646 (<0.001**) | 1409 (31.8) | 310 (57) | 331.136 (<0.001**) | 1215 (30.5) | 504 (54.5) | 482.174 (<0.001**) |
| Normal, $\geq 40$ | 2979 (68.1) | 248 (44.3) |  | 2960 (68.2) | 267 (43) |  | 2775 (69.5) | 452 (45.5) |  |
| Triglycerides (mg/dL) |  |  |  |  |  |  |  |  |  |
| Normal, <150 | 3202 (72.8) | 352 (62.4) | 63.891 (<0.001**) | 3202 (73.4) | 352 (57.2) | 157.039 (<0.001**) | 2953 (73.9) | 601 (60.7) | 163.009 (<0.001**) |
| High, $\geq 150$ | 1278 (27.2) | 213 (37.6) |  | 1240 (26.6) | 251 (42.8) |  | 1107 (26.1) | 384 (39.3) |  |
| Systolic blood pressure ( mmHg ) |  |  |  |  |  |  |  |  |  |
| Normal, <140 | 7839 (88.1) | 803 (73.9) | 274.545 (<0.001**) | 7780 (88.2) | 862 (73.6) | 292.424 (<0.001**) | 7207 (88.9) | 1435 (74.9) | 434.219 (<0.001**) |
| High, $\geq 140$ | 1434 (11.9) | 335 (26.1) |  | 1402 (11.8) | 367 (26.4) |  | 1192 (11.1) | 577 (25.1) |  |
| Diastolic blood pressure ( mmHg ) |  |  |  |  |  |  |  |  |  |
| Normal, <90 | 8820 (95.6) | 1075 (94.4) | 4.635 (0.252) | 8729 (95.5) | 1166 (94.7) | 2.729 (0.255) | 7992 (95.6) | 1903 (94.6) | 6.492 (0.155) |
| High, $\geq 90$ | 453 (4.4) | 63 (5.6) |  | 453 (4.5) | 63 (5.3) |  | 407 (4.4) | 109 (5.4) |  |
| Heart rate (beats/minute) |  |  |  |  |  |  |  |  |  |
| Normal, <90 | 8333 (90) | 1032 (92) | 6.734 (0.102) | 8310 (90.6) | 1055 (86) | 37.262 (0.002**) | 7588 (90.4) | 1777 (89) | 5.769 (0.192) |
| High, $\geq 90$ | 940 (10) | 106 (8) |  | 872 (9.4) | 174 (14) |  | 811 (9.6) | 235 (11) |  |
| Hypertension 6270 (72.7) $305(31) \quad 1266.884(<0.001 * *) 6239(72.8) \quad 360$ (30.2) 1334.567 |  |  |  |  |  |  |  |  |  |
| No | 6270 (72.7) | 305 (31) | 1266.884 (<0.001**) | 6239 (72.8) | 336 (30.2) | 1334.5670 (<0.001**) | 5997 (75.3) | 578 (32.6) | 2154.929 (<0.001**) |
| Yes | 3003 (27.3) | 833 (69) |  | 2943 (27.2) | 893 (69.8) |  | 2402 (24.7) | 1434 (67.4) |  |
|  |  |  |  |  |  |  |  |  |  |
| Low, <3.8 | 8461 (92.9) | 970 (86.4) | 95.782 (<0.001**) | 8409 (93.1) | 1022 (84.6) | 161.235 (<0.001**) | 7725 (93.4) | 1706 (86.2) | 189.581 (<0.001**) |
| Normal $\geq 3.8$ | 812 (7.1) | 168 (13.6) |  | 773 (76.9 | 207 (15.4) |  | 674 (6.6) | 306 (13.8) |  |
| CRP (mg/dL) |  |  |  |  |  |  |  |  |  |
| Normal, <0.3 | 5933 (67.7) | 616 (55.6) | 103.052 (<0.001**) | 5902 (68) | 647 (52.5) | 168.859 (<0.001**) | 5456 (68.7) | 1093 (54.9) | 216.738 (<0.001**) |
| High, $\geq 0.3$ | 3340 (32.3) | 522 (44.4) |  | 3280 (32) | 582 (47.5) |  | 2943 (31.3) | 919 (45.1) |  |
| Allostatic load |  |  |  |  |  |  |  |  |  |
| Normal, <3 | 7094 (80) | 701 (64.8) | 214.968 (<0.001**) | 7254 (81.8) | 541 (45.8) | 1215.600 (<0.001**) | 6693 (82.3) | 1102 (57.4) | 933.722 (<0.001**) |
| High, $\geq 3$ | 2179 (20) | 437 (35.2) |  | 1928 (18.2) | 688 (54.2) |  | 1706 (17.7) | 910 (42.6) |  |

BMI, body mass index; CRP, C-reactive protein; HbA1C, hemoglobin A1c; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoproteins.

Table 4. Predictive Factors Associated with Allostatic Load

| Variables | Unadjusted |  |  | Adjusted |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | OR | 95\% CI | P | OR | 95\% CI | P |
| Race |  |  |  |  |  |  |
| Non-Hispanic white | 1.00 |  |  | 1.00 |  |  |
| Non-Hispanic black | 1.81 | 1.48-2.21 | $<0.001 * *$ | 1.99 | 1.64-2.41 | $<0.001^{* *}$ |
| Mexican and Other Hispanic | 1.23 | 1.00-1.53 | 0.050 | 1.42 | 1.13-1.77 | 0.003** |
| Other | 0.67 | 0.47-0.96 | 0.030 | 0.74 | 0.51-1.07 | 0.102 |
| Income to poverty ratio |  |  |  |  |  |  |
| <1.3 | 1.82 | 1.70-1.96 | 0.016** | 1.76 | 1.65-1.89 | 0.001** |
| 1.3 to 3.5 | 1.58 | 1.49-1.68 | $<0.001 * *$ | 1.54 | 1.46-1.64 | $<0.001^{* *}$ |
| >3.5 | 1.00 |  |  | 1.00 |  |  |
| Marital status |  |  |  |  |  |  |
| Single | 0.84 | 0.77-0.92 | $0.001 * *$ | 0.82 | 0.75-0.91 | $<0.001^{* *}$ |
| Married/Living w/Partner | 1.00 |  |  | 1.00 |  |  |
| Behavioral |  |  |  |  |  |  |
| PA |  |  |  |  |  |  |
| Inactive | 1.51 | 1.47-1.57 | <0.001** | 1.54 | 1.49-1.60 | <0.001** |
| Insufficiently active | 1.28 | 1.21-1.37 | $<0.001 * *$ | 1.32 | 1.24-1.42 | $<0.001^{* *}$ |
| Meeting guidelines | 1.00 |  |  | 1.00 |  |  |
| Sleep problems |  |  |  |  |  |  |
| Yes | 1.44 | 1.26-1.66 | $<0.001 * *$ | 1.39 | 1.21-1.59 | $<0.001^{* *}$ |
| No | 1.00 |  |  | 1.00 |  |  |
|  |  |  |  |  |  |  |
| Current | 1.28 | 1.08-1.52 | 0.005 | 1.13 | 0.96-1.34 | 0.139 |
| Past | 1.30 | 1.13-1.49 | 0.001** | 1.40 | 1.21-1.62 | <0.001** |
| Nonsmoker | 1.00 |  |  | 1.00 |  |  |
| Alcohol |  |  |  |  |  |  |
| Nondrinker | 0.50 | 0.44-0.57 | <0.001** | 0.54 | 0.47-0.62 | $<0.001 * *$ |
| Moderate drinking | 0.68 | 0.59-0.77 | $<0.001 * *$ | 0.85 | 0.73-0.98 | 0.024 |
| Excessive drinking | 1.00 |  |  | 1.00 |  |  |
| Weak/failing kidneys |  |  |  |  |  |  |
| Yes | 1.00 |  |  | 1.00 |  |  |
| No | 0.42 | 0.32-0.55 | $<0.001 * *$ | 0.47 | 0.37-0.62 | <0.001** |
| Physical health not good (past month), days |  |  |  |  |  |  |
| <15 | 1.73 | 1.53-1.95 | $<0.001 * *$ | 1.67 | 1.38-1.89 | <0.001** |
| 15 to 30 | 1.00 |  |  | 1.00 |  |  |
| Mental health not good (past month), days |  |  |  |  |  |  |
| <15 | 1.32 | 1.13-1.54 | 0.001** | 1.37 | 1.17-1.60 | <0.001** |
| 15 to 30 | 1.00 |  |  | 1.00 |  |  |
| General health condition |  |  |  |  |  |  |
| Excellent, very good | 1.00 |  |  | 1.00 |  |  |
| Good/fair | 2.62 | 2.27-3.03 | $<0.001 * *$ | 2.58 | 2.24-2.97 | $<0.001^{* *}$ |
| Poor | 6.69 | 4.91-9.12 | $<0.001 * *$ | 6.30 | 4.62-8.60 | $<0.001 * *$ |
| Duration of diabetes, years |  |  |  |  |  |  |
| <5 | 4.81 | 3.17-7.29 | <0.001** | 4.11 | 2.71-6.25 | <0.001** |
| 5 to 9 | 5.02 | 3.93-6.40 | $<0.001 * *$ | 4.28 | 3.37-5.43 | $<0.001 * *$ |
| $\geq 10$ | 1.00 |  |  | 1.00 |  |  |
| Waist to height ratio |  |  |  |  |  |  |
| 03 to $<0.5$ | 1.00 |  |  | 1.00 |  |  |
| 0.5 to $<0.7$ | 11.88 | 7.59-18.60 | $<0.001 * *$ | 11.16 | 7.07-17.62 | <0.001** |
| $\geq 0.7$ | 85.18 | 53.40-135.88 | $<0.001 * *$ | 79.96 | 49.44-129.32 | $<0.001^{* *}$ |
| HDL-C, mg/dL |  |  |  |  |  |  |
| Low, <40 | 1.40 | 1.17-1.66 | $<0.001 * *$ | 1.40 | 1.18-1.66 | $<0.001 * *$ |
| Normal, $\geq 40$ | 1.00 |  |  | 1.00 |  |  |
|  |  |  |  |  |  |  |
| Normal, <150 | 3.63 | 3.06-4.32 | $<0.001 * *$ | 3.57 | 2.99-4.26 | $<0.001^{* *}$ |
| High, $\geq 150$ | 1.00 |  |  | 1.00 |  |  |

Table 4. (Continued)

| Variables | Unadjusted |  |  | Adjusted |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | OR | 95\% CI | P | OR | 95\% CI | P |
| Chronic conditions |  |  |  |  |  |  |
| CVD |  |  |  |  |  |  |
| Yes | 2.16 | 1.77-2.65 | <0.001** | 1.74 | 1.39-2.18 | <0.001** |
| No | 1.00 |  |  | 1.00 |  |  |
| Diabetes |  |  |  |  |  |  |
| Yes | 5.17 | 4.18-6.41 | $<0.001^{* *}$ | 4.67 | 3.79-5.74 | $<0.001^{* *}$ |
| No | 1.00 |  |  | 1.00 |  |  |
| CVD/diabetes |  |  |  |  |  |  |
| Yes | 3.40 | 2.94-3.94 | $<0.001^{* *}$ | 3.13 | 2.71-3.62 | $<0.001^{* *}$ |
| No | 1.00 |  |  | 1.00 |  |  |

$* * P<0.001$. Adjusted for age, gender, and other health conditions (liver diseases and cancer).
CI, confidence interval; OR, odds ratio.

Having poor mental and physical health was associated with a higher level of AL. This is also evidenced by a study that showed people with high AL rated their physical health much worse and reported a greater overall smoking history and consumption of alcohol. ${ }^{31}$ A national sample of middleaged and elderly Taiwanese depicted a significant association between biomarkers of stressful experiences and profiles of physical and mental functioning. ${ }^{32}$ Other studies indicate that mental health might also arise as a result of stress experienced from inequalities in social and economic opportunities and environmental conditions, ${ }^{33}$ further explaining the due effect of chronic stress on the mental health functioning of individuals.

## Limitations

The study was a cross sectional survey that does not follow participants over time; hence, it lacks a temporal order of the factors or evaluates causality and does not allow making causal inferences. Due to the nature of the NHANES data, we did not ascertain the willingness of the individuals to participate or who refused to participate, in which there is a possibility that our results could be under- or overestimated reporting. Some of the variables are self-reported and may possess reporting bias unlike the measurement of the biomarkers and physiologic measures of chronic stress. In addition, all biomarkers' measurements were performed only once, so some phenotype and laboratory markers such as the blood pressure and fibrinogen could be biased, as they can easily be modified by temporal diseases or clinical facts. The study also fails to assess the full impact of chronic stress related to health and wellbeing. Finally, the different AL definitions across different studies makes difficult on the comparison of the results across the studies.

## Conclusion

Our study strongly shows the interplay between higher AL and other variables, such as having CVD and diabetes as well as having both CVD and diabetes, being physically inactive or not meeting the physical exercise guidelines, having sleeping problems, being a past or current smoker, excessive drinking habits, weak or failing kidneys, and poor mental health and physical health. It is recommended to focus and act on those modifiable lifestyle behaviors, such as reducing substance use, participating in regular PA, and
experiencing psychosocial support interventions to reduce higher AL for averting CVD and diabetes conditions. There is a need to conduct more longitudinal/cohort studies to better measure the manifestation and biomarkers of AL to reduce the burden on chronic conditions.

## Ethics Approval and Consent to Participate

The study used secondary data from Center for Disease Control: The National Health and Nutrition Examination Survey (NHANES) and does not require ethical approval.

## Availability of Data and Materials

NHANES data and reports (https://wwwn.cdc.gov/nchs/ nhanes/Default.aspx) are available upon request from the corresponding author.

## Authors' Contributions

P.M. and M.H. conceived and designed the study. M.H. analyzed the data. M.H., P.M., and S.B. assisted with the analysis, interpreted the data, and wrote the results section of the article. P.M., M.H., S.B., and J.K. conducted detailed analyses and synthesis of the article. All authors critically reviewed and approved the article and meet ICMJE criteria for authorship.

## Acknowledgments

We thank CDC for providing the full data set to conduct this imperative study. We also thank the Council for the Development of Social Science Research in Africa (CODESRIA) for providing support to the lead author to perform the study. Finally, the lead author acknowledges fellowship support from the National Institutes of Health R25 fellowship programs- HIV Intervention Science Training Program for Underrepresented New Investigators (HISTP program) and the Program to Increase Diversity in Behavioral Medicine and Sleep Disorders Research (PRIDE program).

## Author Disclosure Statement

No conflicting financial interests exist.

## Funding Information

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## References

1. Logan JG, Barksdale DJ. Allostasis and allostatic load: Expanding the discourse on stress and cardiovascular disease. J Clin Nurs 2008;17(7B):201-208.
2. Bauer UE, Briss PA, Goodman RA, et al. Prevention of chronic disease in the 21st century: Elimination of the leading preventable causes of premature death and disability in the USA. Lancet 2014;384:45-52.
3. The Lancet. Life, death, and disability in 2016. Lancet 2017;390:1083.
4. Ward BW, Schiller JS, Goodman RA. Multiple chronic conditions among US adults: A 2012 update. Prev Chronic Dis 2014;11:130389.
5. Mattei J, Demissie S, Falcon LM, et al. Allostatic load is associated with chronic conditions in the Boston Puerto Rican Health Study. Soc Sci Med 2010;70:1988-1996.
6. Sabbah W, Watt RG, Sheiham A, et al. Effects of allostatic load on the social gradient in ischaemic heart disease and periodontal disease: Evidence from the Third National Health and Nutrition Examination Survey. J Epidemiol Community Health 2008;62:415-420.
7. Maloney EM, Gurbaxani BM, Jones JF, et al. Chronic fatigue syndrome and high allostatic load. Pharmacogenomics 2006;7:467-473.
8. Robertson T, Beveridge G, Bromley C. Allostatic load as a predictor of all-cause and cause-specific mortality in the general population: Evidence from the Scottish Health Survey. Abe T, ed. PLoS One 2017;12:e0183297.
9. Seeman TE, Gruenewald TL, Cohen S, et al. Social relationships and their biological correlates: Coronary Artery Risk Development in Young Adults (CARDIA) study. Psychoneuroendocrinology 2014;43:126-138.
10. McEwen BS, Tucker P. Critical biological pathways for chronic psychosocial stress and research opportunities to advance the consideration of stress in chemical risk assessment. Am J Public Health 2011;101(Suppl 1):S131.
11. Seeman TE, Singer BH, Ryff CD, et al. Social relationships, gender, and allostatic load across two age cohorts. Psychosom Med 2002;64:395-406.
12. Bushman BA. Physical activity guidelines for Americans: The relationship between physical activity and health. ACSM's Health Fit J 2019;23:5-9.
13. US AY-UD of H and HS and, 2015 undefined. Dietary guidelines for Americans. core.ac.uk. Accessed at https:// core.ac.uk/download/pdf/188226713.pdf on August 30, 2021.
14. McEwen BS. Stress and the individual. Arch Intern Med 1993;153:2093.
15. Hawkley LC, Lavelle LA, Berntson GG, et al. Mediators of the relationship between socioeconomic status and allostatic load in the Chicago Health, Aging, and Social Relations Study (CHASRS). Psychophysiology 2011;48:1134-1145.
16. McEwen BS, Tucker P. Critical biological pathways for chronic psychosocial stress and research opportunities to advance the consideration of stress in chemical risk assessment. Am J Public Health 2011;101(Suppl 1):S131-S139.
17. Seeman T, Epel E, Gruenewald T, et al. Socio-economic differentials in peripheral biology: Cumulative allostatic load. Ann $N$ Y Acad Sci 2010;1186:223-239.
18. McEwen BS. Protective and damaging effects of stress mediators: Central role of the brain. Dialogues Clin Neurosci 2006;8:367-381.
19. Hormenu T, Shoup EM, Osei-Tutu NH, et al. Stress measured by allostatic load varies by reason for immigration, age at immigration, and number of children: The Africans
in America Study. Int J Environ Res Public Health 2020; 17:4533.
20. Juster R-P, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev 2010;35:2-16.
21. Schulz AJ, Mentz G, Lachance L, et al. Associations between socioeconomic status and allostatic load: Effects of neighborhood poverty and tests of mediating pathways. Am J Public Health 2012;102:1706-1714.
22. Gebreab SY, Diez-Roux AV, Hickson DA, et al. The contribution of stress to the social patterning of clinical and subclinical CVD risk factors in African Americans: The Jackson Heart Study. Soc Sci Med 2012;75:1697-1707.
23. Steptoe A, Feldman PJ. Neighborhood problems as sources of chronic stress: Development of a measure of neighborhood problems, and associations with socioeconomic status and health. Ann Behav Med 2001;23:177-185.
24. McEwen BS. Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol 2008;583:174-185.
25. Fitzgerald N, Himmelgreen D, Damio G, et al. Acculturation, socioeconomic status, obesity and lifestyle factors among low-income Puerto Rican women in Connecticut, U.S., 1998-1999. Rev Panam Salud Pública 2006;19:306313.
26. Gay JL, Salinas JJ, Buchner DM, et al. Meeting physical activity guidelines is associated with lower allostatic load and inflammation in Mexican Americans. J Immigr Minor Health 2015;17:574-581.
27. McEwen BS, Karatsoreos IN. Sleep deprivation and circadian disruption. Sleep Med Clin 2015;10:1-10.
28. Chen X, Redline S, Shields AE, et al. Associations of allostatic load with sleep apnea, insomnia, short sleep duration, and other sleep disturbances: Findings from the National Health and Nutrition Examination Survey 2005 to 2008. Ann Epidemiol 2014;24:612-619.
29. Tremblay A, Chaput J-P. Obesity: The allostatic load of weight loss dieting. Physiol Behav 2012;106:16-21.
30. Deuster P. Allostatic load and health status of African Americans and Whites. Am J Health Behav 2011;35:641653.
31. de Castro AB, Voss JG, Ruppin A, et al. Stressors among Latino day laborers. $A A O H N$ J 2010;58:185-196.
32. Seplaki CL, Goldman N, Weinstein M, et al. How are biomarkers related to physical and mental well-being? $J$ Gerontol A Biol Sci Med Sci 2004;59:201-217.
33. Rodriquez EJ, Livaudais-Toman J, Gregorich SE, et al. Relationships between allostatic load, unhealthy behaviors, and depressive disorder in U.S. adults, 2005-2012 NHANES. Prev Med 2018;110:9-15.

> Address correspondence to:
> Peter Memiah, DrPH, MSc
> Medicine, Epidemiology and Public Health
> Division of Epidemiology and Prevention
> Institute of Human Virology University of Maryland School of Medicine 725 West Lombard Street, Room N345
> Baltimore, MD 21201

USA
E-mail: pmemiah@ihv.umaryland.edu


[^0]:    ${ }^{1}$ Division of Epidemiology and Prevention, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
    ${ }^{2}$ Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, USA.
    ${ }^{3}$ College of Health Sciences and Professions, Ohio University, Athens, Ohio, USA.
    ${ }_{5}^{4}$ Department of Nursing, Fortis Institute, Pensacola, Florida, USA.
    ${ }^{5}$ Department of Public Health, University of Reno, Reno, Arizona, USA.
    ${ }^{6}$ Centre of for Minority Health and Health Disparities Research and Education, Xavier University of Louisiana, New Orleans, Louisiana, USA.
    ${ }_{8}^{7}$ Department of Medicine, University of Maryland School of Medicine Midtown Campus, Baltimore, Maryland, USA.
    ${ }^{8}$ Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
    © Peter Memiah et al., 2021; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

[^1]:    $* * P<0.001$.
    CVD cardiovascular disease.

